PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo (Q33779210)

29 July 2017

title

PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo (English)

1 reference

29 July 2017

Jin-gui Ma

1

1 reference

29 July 2017

He Huang

2

1 reference

29 July 2017

Si-meng Chen

3

1 reference

29 July 2017

Yi Chen

4

1 reference

29 July 2017

Xian-liang Xin

5

1 reference

29 July 2017

Li-ping Lin

6

1 reference

29 July 2017

Jian Ding

7

1 reference

29 July 2017

Hong Liu

8

1 reference

29 July 2017

Ling-hua Meng

9

1 reference

29 July 2017

language of work or name

English

0 references

publication date

22 December 2010

1 reference

Breast Cancer Research and Treatment

29 July 2017

published in

1 reference

29 July 2017

volume

130

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

85-96

1 reference

29 July 2017

cites work

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Src family kinases in tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Structural basis for the autoinhibition of c-Abl tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with anti-tumor and anti-angiogenic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

New colorimetric cytotoxicity assay for anticancer-drug screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Focal adhesion kinase: the first ten years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Integrin-regulated FAK-Src signaling in normal and cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

The interplay between Src and integrins in normal and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

The hepatocyte growth factor regulatory factors in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

Src inhibitors in early breast cancer: a methodology, feasibility and variability study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

New concepts regarding focal adhesion kinase promotion of cell migration and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1302-4

10.1007/S10549-010-1302-4

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1020449508

0 references

1 reference